How does ANUHPHR's PE Ratio compare to its peers?

ANUHPHR is good value based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (20.5x).

How does ANUHPHR's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

ANUHPHR is good value based on its Price-To-Earnings Ratio (19.2x) compared to the Indian Pharmaceuticals industry average (36.3x).

What is ANUHPHR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ANUHPHR's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of ANUHPHR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ANUHPHR (₹226.21) is trading above our estimate of [[fair value]] (₹4.23)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

ANUHPHR Stock Overview

Engages in the manufacture and sale of bulk drugs and chemicals in India. More details

ANUHPHR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	4/6

Rewards

Price-To-Earnings ratio (19.2x) is below the Indian market (32.9x)

Earnings grew by 32.6% over the past year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Dividend of 1.1% is not well covered by free cash flows

My Notes

Capture your thoughts, links and company narrative

Anuh Pharma Limited Competitors

Kopran

BSE:524280

₹10.3b

NGL Fine-Chem

BSE:524774

₹11.1b

Wanbury

BSE:524212

₹9.5b

Lincoln Pharmaceuticals

BSE:531633

₹17.2b

Price History & Performance

Summary of share price highs, lows and changes for Anuh Pharma
Historical stock prices
Current Share Price	₹226.21
52 Week High	₹245.70
52 Week Low	₹208.16
Beta	0.69
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.51%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ANUHPHR	IN Pharmaceuticals	IN Market
7D	4.0%	1.0%	1.6%
1Y	n/a	35.7%	17.5%

Return vs Industry: Insufficient data to determine how ANUHPHR performed against the Indian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ANUHPHR performed against the Indian Market.

Price Volatility

Is ANUHPHR's price volatile compared to industry and market?
ANUHPHR volatility
ANUHPHR Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.1%
10% least volatile stocks in IN Market	4.1%

Stable Share Price: ANUHPHR's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine ANUHPHR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1960	175	Ritesh Shah	www.anuhpharma.com

Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and intermediates. The company also provides corticosteroids, such as anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, and anti-histamines.

Anuh Pharma Limited Fundamentals Summary

How do Anuh Pharma's earnings and revenue compare to its market cap?
ANUHPHR fundamental statistics
Market cap	₹11.36b
Earnings (TTM)	₹590.23m
Revenue (TTM)	₹6.40b

19.2x

P/E Ratio

1.8x

P/S Ratio

Is ANUHPHR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANUHPHR income statement (TTM)
Revenue	₹6.40b
Cost of Revenue	₹4.82b
Gross Profit	₹1.58b
Other Expenses	₹992.05m
Earnings	₹590.23m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	11.78
Gross Margin	24.73%
Net Profit Margin	9.22%
Debt/Equity Ratio	4.5%

How did ANUHPHR perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

21%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/04 05:17
End of Day Share Price	2025/01/03 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anuh Pharma Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kameswari V. S. Chavali	FirstCall Research